Where the science actually stands.
The immune system is one of several threads researchers are pulling on in POTS, and it is a live question rather than a solved one. The National Institute of Neurological Disorders and Stroke is direct about the bigger picture: scientists still do not know exactly what causes POTS. Autoimmunity appears there under emerging research, phrased carefully — researchers think that in some individuals, POTS may be linked to an autoimmune reaction, meaning the immune system mistakenly attacks the body's own tissues.
The Heart Rhythm Society's expert consensus is similarly measured, noting the nerve-supply problems seen in some POTS patients might be due to an autoimmune disease in some cases. Note the qualifiers in both: might, may, some. Anyone who tells you POTS has been shown to be autoimmune is ahead of the evidence — and so is anyone who says the immune system has nothing to do with it.
What is documented: company, not causation.
The most solid observation is that autoimmune conditions and POTS keep turning up in the same people. A 2024 review in the Journal of Personalized Medicine reports that about one in five people with POTS also carries a diagnosed autoimmune disease — Hashimoto's thyroiditis, celiac disease, Sjögren's disease, rheumatoid arthritis, and lupus among them.
That co-occurrence is worth knowing, and it is also frequently over-read. Two conditions appearing together can mean one causes the other, that both share an upstream cause, or that people already under investigation simply accumulate more diagnoses. The association is real; the arrow between them has not been drawn.
Onset timing gets over-read the same way. NINDS notes POTS commonly begins after a pregnancy, major surgery, puberty, physical trauma, or a viral illness. A viral trigger fits an immune explanation — it also fits several others, and the pattern alone does not settle the question.
Why an autoantibody test cannot tell you that you have POTS.
This deserves plain language, because there is a real commercial market in it: several labs sell antibody panels aimed at receptors in the autonomic nervous system, sometimes presented as confirming autoimmune POTS. The evidence does not support that use. A 2022 study in Circulation measured these commercially available autoantibodies in people with POTS and in healthy people, and found concentrations were not significantly different between the groups — healthy controls crossed the tests' own positivity thresholds about as often as POTS patients did. The authors' conclusion was blunt: commercially available autoantibody concentrations alone cannot be used to differentiate patients with POTS from healthy controls.
A positive result therefore does not establish that you have POTS, that your POTS is autoimmune, or that any treatment is warranted. POTS is identified through history, symptoms, orthostatic measurements, and the exclusion of other explanations — not an antibody number.
Testing for a specific autoimmune disease is a different matter. If a clinician suspects Hashimoto's, celiac disease, or lupus, established testing exists and is worth doing — for those conditions. Even there, MedlinePlus notes autoimmune diseases are often hard to diagnose, with usually no single test that settles it.
What it would mean for treatment — and what it doesn't.
A reasonable hope follows from the autoimmune hypothesis: if the immune system drives POTS, calming it should help. That hope has been tested, and the result is a caution rather than a green light.
The one randomized controlled trial in this area, iSTAND, gave intravenous immunoglobulin to POTS patients with moderate to severe symptoms and evidence of autoimmunity, compared against albumin. It did not show a significant difference in symptom outcomes between the groups. Case reports have described benefit for individuals, but case reports are where hypotheses start, not where they are confirmed.
The practical translation: nobody should tell you that treating autoimmunity will resolve your POTS. It has not been shown to. Screening for a coexisting autoimmune condition is still worth doing — because that condition matters on its own terms and may need its own care — rather than because it is a lever that turns POTS off.
Bringing this up with a clinician.
Among the chronic conditions this practice publishes a focus on are POTS and Hashimoto's thyroiditis, and its POTS material describes screening for coexisting autoimmune conditions as one thread an evaluation can follow. The treatment page covers what an examination involves, so this guide won't restate it.
Functional neurology here is complementary care — designed to run alongside a primary care provider, cardiologist, or rheumatologist rather than in place of any of them, and it does not diagnose autoimmune disease. Whoever you talk to about this topic, whether at (775) 507-2000 or elsewhere, a few questions tend to separate evidence from marketing:
- Given what my rheumatologist or primary care provider has already tested, would another evaluation add anything?
- If autoimmune screening comes up, which specific conditions are being screened for — and what would a result actually change about my care?
- Do you consider the autoimmune explanation of POTS established or still unsettled?
- Should I bring recent labs, tilt-table results, or antibody panels I have already paid for?
- What happens at a first conversation, and what does it cost me to find out whether this is a fit?